Pharmafile Logo
Pharmafocus logo
Advanced Search

Idorsia

Showing 4 posts of 4 posts found.

Viatris and Idorsia enter research and development collaboration

February 28, 2024
Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus

Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …

News
48612088061_36c0f87278_b

Idorsia reveals it is working with Neurocrine on new epilepsy drug deal

January 10, 2020
Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …

News

J&J opts in on Idorsia’s candidate for $230m

December 4, 2017
Sales and Marketing Idorsia, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …

News
actelion

Actelion spin-off hit by blow shortly before buyout

June 9, 2017
Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ

Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025